Crystalline chemotherapeutic
View Patent ↗N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it is disclosed.
1. N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1 which, when measured at about −100° C. in the triclinic crystal system and P1 space group with radiation at 0.7107 Å, is characterized by respective lattice parameter values a, b and c of 8.971 ű0.006 Å, 11.646 ű0.008 Å and 19.26 ű0.01 Å and respective α, β and γ values of about 87.67°±0.1°, 90.21°±0.1°, and 76.82°±0.1°.
2. N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1 which, when measured at about 25° C. with radiation at 1.54178 Å, is characterized by a powder diffraction pattern having respective 2θvalues of about 4.5°, 7.7°, 11.7°, 12.2°, 14.6°, 16.9°, 17.7° and 18.4°.
3. A solid formulation comprising an excipient and N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1 which, when measured at about −100° C. in the triclinic crystal system and P1 space group with radiation at 0.7107 Å, is characterized by respective lattice parameter values a, b and c of 8.971 ű0.006 Å, 11.646 ű0.008 Å and 19.26 ű0.01 Å and respective α, β and γ values of about 87.67°±0.1°, 90.21°±0.1°, and 76.82°±0.1° or, when measured at about 25° C. with radiation at 1.54178 Å, characterized by a powder diffraction pattern having respective 2θ values of about 4.5°, 7.7°, 11.7°, 12.2°, 14.6°, 16.9°, 17.7° and 18.4°.
4. A process for making N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼Ethanolate Crystalline Form 1 comprising:
providing a mixture comprising N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea and a solvent comprising ethanol, wherein the N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea is completely dissolved in the solvent; and
causing N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼Ethanolate Crystalline Form 1 to exist in the mixture, which N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1, when isolated and measured at about −100° C. in the triclinic crystal system and P1 space group with radiation at 0.7107 Å, is characterized by respective lattice parameter values a, b and c of 8.971 ű0.006 Å, 11.646 ű0.008 Å and 19.26 ű0.01 Å and respective α, β and γ values of about 87.67°±0.1°, 90.21°±0.1° and 76.82°±0.1°.
5. The process of claim 4 further comprising isolating the N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1.